Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 8/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15017981 | 0.99 | CYP2D6 (0.54) | CYP2D6ALDH1A1TSHRCYP3A4CYP2C9 | |
| SCHEMBL2089472 | 0.92 | CYP2D6 (0.53) | CYP2D6ALDH1A1TSHRCYP3A4CYP2C9 | |
| SCHEMBL4609435 | 0.86 | CYP3A4 (0.65) | CYP2D6ALDH1A1CYP3A4CYP2C9CYP2C19 | |
| Trifluoroacetic Acid SCHEMBL29366988 | 0.85 | CYP2D6 (0.50) | CYP2D6ALDH1A1TSHRCYP3A4CYP2C9 | |
| SCHEMBL3498095 | 0.84 | CYP2D6 (0.56) | CYP2D6ALDH1A1TSHRCYP3A4CYP2C9 | |
| SCHEMBL14081425 | 0.84 | CYP2D6 (0.56) | CYP2D6ALDH1A1TSHRCYP3A4CYP2C9 | |
| SCHEMBL13744181 | 0.84 | CYP2D6 (0.60) | CYP2D6ALDH1A1TSHRCYP3A4CYP2C9 | |
| SCHEMBL31712017 | 0.83 | CYP2D6 (0.60) | CYP2D6ALDH1A1TSHRCYP3A4CYP2C9 | |
| SCHEMBL1975609 | 0.83 | CYP2D6 (0.57) | CYP2D6ALDH1A1TSHRCYP3A4CYP2C9 | |
| SCHEMBL16999964 | 0.83 | CYP2D6 (0.55) | CYP2D6ALDH1A1TSHRCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240300965-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-09-12 | — | — | US | disclosed |
| US-11999746-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-06-04 | — | — | US | disclosed |
| US-20200055863-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-02-20 | — | — | US | disclosed |
| WO-2019238057-A1 | APPLICATION OF FSO2N3 IN PREPARATION OF AZIDE | 中国科学院上海有机化学研究所 | 2019-12-19 | — | — | WO | disclosed |
| US-10428078-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-01 | — | — | US | disclosed |
| EP-3172211-B1 | TRICYCLIC IMIDAZO-PYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY LP-PLA2 | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-07-03 | — | — | EP | disclosed |
| US-20190023715-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-24 | — | — | US | disclosed |
| US-10125141-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-11-13 | — | — | US | disclosed |
| US-20170204109-A1 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-07-20 | — | — | US | disclosed |
| EP-3172211-A1 | COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-05-31 | — | — | EP | disclosed |
| US-7863450-B2 | Compounds comprising an oxazoline or thiazoline moiety, processes for making them, and their uses | UCB PHARMA, S.A. (BE) | 2011-01-04 | — | — | US | disclosed |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| EP-2166846-A1 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008156726-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080161331-A1 | Compounds Comprising an Oxazoline or Thiazoline Moiety, Processes for Making Them, and Their Uses | UCB PHARMA, S.A. (BE) | 2008-07-03 | — | — | US | disclosed |
| US-20080161331-A1 | Compounds Comprising an Oxazoline or Thiazoline Moiety, Processes for Making Them, and Their Uses | UCB PHARMA, S.A. (BE) | 2008-07-03 | — | — | US | disclosed |
| WO-2008005423-A1 | IMPROVED METHOD OF MAKING SUFENTANIL | CAMBREX CHARLES CITY, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20020082420-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-06-27 | — | — | US | disclosed |
| EP-1163242-A2 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESSES FOR PREPARING THEM | Boehringer Ingelheim Pharma KG (DE) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000055162-A2 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESSES FOR PREPARING THEM | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055863-A1 | COMPOUNDS | PLAAT2, PLA2G12A, PLA2G1B | CYP2D6 3845/4885ALDH1A1 2222/4885TSHR 4736/4885 |
| US-20190023715-A1 | COMPOUNDS | PLAAT2, PLA2G12A, PLA2G1B | CYP2D6 3845/4885ALDH1A1 2222/4885TSHR 4736/4885 |
| US-20020082420-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | PKD1, REN, CYP11B1 | CYP2D6 969/4885ALDH1A1 1857/4885TSHR 2196/4885 |
| US-10125141-B2 | Compounds | PLAAT2, PLA2G12A, PLA2G1B | CYP2D6 3845/4885ALDH1A1 2222/4885TSHR 4736/4885 |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | JAK2, JAK3, JAK1 | CYP2D6 4014/4885ALDH1A1 3244/4885TSHR 1368/4885 |
| US-10428078-B2 | Compounds | PLAAT2, PLA2G12A, PLA2G1B | CYP2D6 3845/4885ALDH1A1 2222/4885TSHR 4736/4885 |
| US-20080161331-A1 | Compounds Comprising an Oxazoline or Thiazoline Moiety, Processes for Making Them, and Their Uses | NR1H3, NR1I3, NR1I2 | CYP2D6 281/4885ALDH1A1 977/4885TSHR 31/4885 |
| US-20240300965-A1 | COMPOUNDS | PLAAT2, PLA2G12A, PLA2G1B | CYP2D6 3845/4885ALDH1A1 2222/4885TSHR 4736/4885 |
| US-11999746-B2 | Compounds | PLAAT2, PLA2G12A, PLA2G1B | CYP2D6 3845/4885ALDH1A1 2222/4885TSHR 4736/4885 |
| US-20170204109-A1 | Compounds | PLAAT2, PLA2G12A, PLA2G1B | CYP2D6 3845/4885ALDH1A1 2222/4885TSHR 4736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.